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Background
An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate 
malaria vaccine RTS,S/AS01 is being conducted in seven African countries. 
Methods
From March 2009 through January 2011, we enrolled 15,460 children in two age 
categories — 6 to 12 weeks of age and 5 to 17 months of age — for vaccination with 
either RTS,S/AS01 or a non-malaria comparator vaccine. The primary end point of 
the analysis was vaccine efficacy against clinical malaria during the 12 months 
after vaccination in the first 6000 children 5 to 17 months of age at enrollment who 
received all three doses of vaccine according to protocol. After 250 children had an 
episode of severe malaria, we evaluated vaccine efficacy against severe malaria in 
both age categories.
Results
In the 14 months after the first dose of vaccine, the incidence of first episodes of 
clinical malaria in the first 6000 children in the older age category was 0.32 epi-
sodes per person-year in the RTS,S/AS01 group and 0.55 episodes per person-year 
in the control group, for an efficacy of 50.4% (95% confidence interval [CI], 45.8 to 
54.6) in the intention-to-treat population and 55.8% (97.5% CI, 50.6 to 60.4) in the 
per-protocol population. Vaccine efficacy against severe malaria was 45.1% (95% CI, 
23.8 to 60.5) in the intention-to-treat population and 47.3% (95% CI, 22.4 to 64.2) 
in the per-protocol population. Vaccine efficacy against severe malaria in the com-
bined age categories was 34.8% (95% CI, 16.2 to 49.2) in the per-protocol popula-
tion during an average follow-up of 11 months. Serious adverse events occurred with 
a similar frequency in the two study groups. Among children in the older age cat-
egory, the rate of generalized convulsive seizures after RTS,S/AS01 vaccination was 
1.04 per 1000 doses (95% CI, 0.62 to 1.64).
Conclusions
The RTS,S/AS01 vaccine provided protection against both clinical and severe ma-
laria in African children. (Funded by GlaxoSmithKline Biologicals and the PATH 
Malaria Vaccine Initiative; RTS,S ClinicalTrials.gov number, NCT00866619.)
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Each year, malaria occurs in approx-imately 225 million persons worldwide, and 781,000 persons, mostly African chil-
dren, die from the disease.1 During the past de-
cade, the scale-up of malaria-control interven-
tions has resulted in considerable reductions in 
morbidity and mortality associated with malaria 
in parts of Africa.2,3 However, malaria continues 
to pose a major public health threat. A malaria 
vaccine, deployed in combination with current 
malaria-control tools, could play an important 
role in future control and eventual elimination of 
malaria in Africa.4
The RTS,S vaccine that targets the circumspo-
rozoite protein and is given with an adjuvant sys-
tem (AS01 or AS02) has consistently shown pro-
tection against Plasmodium falciparum malaria in 
children and infants in phase 2 trials.5-10 The vac-
cine had an acceptable side-effect profile and was 
immunogenic in children who were 6 weeks of 
age or older. In addition, the vaccine could be ad-
ministered safely with other childhood vaccines8,11 
and provided protection against severe malaria.5 
Here, we report the initial results of an ongoing 
phase 3 trial being conducted at 11 centers in 
7 African countries (Fig. 1 in the Supplementary 
Appendix, available with the full text of this 
article at NEJM.org).
Me thods
Study Design
Detailed methods are presented in the Supplemen-
tary Appendix and have been reported previously.12-15 
This randomized, controlled, double-blind trial 
was designed to evaluate vaccine efficacy, safety, 
reactogenicity, and immunogenicity in children 
up to 32 months after the administration of the 
first dose of vaccine. The trial included two age 
categories: children 6 to 12 weeks of age and 
those 5 to 17 months of age at enrollment. The 
trial included three study groups in each age cat-
egory: children who received all three doses of 
the RTS,S/AS01 vaccine administered at 1-month 
intervals and who were scheduled to receive a 
booster dose 18 months after the third dose, 
children who received the RTS,S/AS01 primary vac-
cination series without a booster, and a control 
group who received a non-malaria comparator vac-
cine. This first analysis combines the first two 
groups (referred to as the RTS,S/AS01 group) and 
compares this group with the control group (Fig. 2 
in the Supplementary Appendix). Children in the 
younger age category received the RTS,S/AS01 vac-
cine along with routine childhood vaccinations 
beginning at 6 weeks of age.
The coprimary end points of the trial — vaccine 
efficacy against clinical malaria after 12 months 
of follow-up in each age category — have been 
completed for the first 6000 children enrolled in 
the older age category. Vaccine efficacy against 
severe malaria will be reported after 12 months 
of follow-up of the first 6000 children enrolled in 
each age category. Accordingly, vaccine efficacy 
against both clinical and severe malaria in the 
older age category is presented here, and find-
ings regarding efficacy will be presented for the 
younger age category in approximately 1 year, after 
the first 6000 children in that age category have 
completed 12 months of follow-up. A secondary 
analysis of vaccine efficacy against severe ma-
laria in the pooled age categories was planned to 
take place when at least one severe malaria epi-
sode had occurred in at least 250 children. This 
milestone was reached on May 31, 2011. Vaccine 
efficacy against severe disease in the pooled age 
categories is restricted to data obtained up to 
this date. Data for children who received a boost-
er dose of vaccine before May 31, 2011, were 
censored at the time of booster vaccination.
The trial protocol, which is available at NEJM 
.org, was approved by the ethical review board 
and national regulatory authority at each study 
center and partner institution. Written informed 
consent was obtained from the children’s par-
ents or guardians (Table 1 in the Supplementary 
Appendix). The trial was undertaken in accor-
dance with the provisions of the Good Clinical 
Practice Guidelines.16
Randomization and Vaccination
From March 2009 through January 2011, we ran-
domly assigned 15,460 children to one of the 
three original study groups in a 1:1:1 ratio. Com-
parator vaccines were rabies vaccine (VeroRab, 
Sanofi-Pasteur) for children 5 to 17 months of age 
at enrollment and meningococcal serogroup C con-
jugate vaccine (Menjugate, Novartis) for children 
6 to 12 weeks of age at enrollment. All vaccines 
were administered intramuscularly.
Surveillance for Clinical and Severe Malaria
Passive surveillance for malaria was undertaken 
from the time of the administration of the first 
dose of vaccine until the end of the study. Par-
ticipants were encouraged to seek care at a health 
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facility within the study area for any illness, and 
transportation was facilitated. All participants 
who presented to a study facility with a reported 
or measured fever during the previous 24 hours 
were evaluated for malaria (for details, see the 
Supplementary Appendix).
The primary efficacy end point for this analy-
sis was the incidence of clinical malaria, which 
was defined as an illness in a child who was 
brought to a study facility with a temperature of 
37.5°C or more and P. falciparum asexual parasite-
mia (>5000 parasites per cubic millimeter) or a case 
of malaria meeting the primary case definition 
of severe malaria.12 Different parasite thresholds 
were used for secondary case definitions (Tables 1 
and 2, and Table 2 in the Supplementary Appen-
dix). Participants who were hospitalized were evalu-
ated for severe malaria on the basis of a protocol-
defined algorithm (Table 3 in the Supplementary 
Appendix).12
Safety Surveillance
Data regarding serious adverse events were collect-
ed throughout the trial by passive surveillance. 
Seizures that occurred within 7 days after vac-
cination were analyzed according to Brighton 
Collaboration guidelines.17 Verbal autopsies were 
conducted on deaths that occurred outside study 
facilities.18 Information was collected on all un-
solicited reports of adverse events that occurred 
within 30 days after vaccination and on reacto-
genicity within 7 days after vaccination among 
the first 200 children in the older age category at 
each study center (Table 4 in the Supplementary 
Appendix).
Immunogenicity
Anti–circumsporozoite antibody titers were mea-
sured by means of enzyme-linked immunosor-
bent assay19 in the first 200 children in the older 
age category at each study center at enrollment 
and 1 month after the administration of the third 
dose of a study vaccine. The threshold for a posi-
tive titer was 0.5 EU per milliliter.
Laboratory and Radiologic Procedures
Laboratory and radiologic procedures are de-
scribed in the Supplementary Appendix and have 
been reported previously.13
Study Oversight
The trial was sponsored by GlaxoSmithKline Bio-
logicals (GSK), the vaccine developer and manu-
facturer, and funded by both GSK and the Pro-
gram for Appropriate Technology in Health (PATH) 
Malaria Vaccine Initiative, which received a grant 
from the Bill and Melinda Gates Foundation. All 
study centers received study grants from the Ma-
laria Vaccine Initiative, which also provided 
funding for authors’ travel and accommodations 
related to this trial. All the authors reviewed all 
manuscript drafts, approved the final version of 
the manuscript, and made the decision to submit 
it for publication. The Clinical Trials Partnership 
Committee and Writing Group vouch for the com-
pleteness and accuracy of the data presented and 
for the fidelity of this report to the trial protocol.
Statistical Analysis
Statistical methods have been described previously.15 
We used Cox regression models (1 minus the haz-
ard ratio) to evaluate vaccine efficacy against the 
first or only episode of clinical malaria in the old-
er age category, using the study center as a strati-
fication factor that allowed for differential base-
line hazards. The proportionality of hazards was 
evaluated by Schoenfeld residuals and models, in-
cluding time-varying covariates. Secondary analy-
ses included evaluations of other clinical case defi-
nitions and multiple episodes of clinical malaria 
by means of negative binomial regression. Vac-
cine efficacy against severe malaria, which was 
defined as 1 minus the risk ratio, is expressed 
as a percent and is presented with Fisher’s exact 
P values. All end points are presented with 95% 
confidence intervals except for the primary ef-
ficacy end point, which is presented with 97.5% 
confidence intervals.
Primary analyses of vaccine efficacy were 
based on the per-protocol population, which in-
cluded all participants who received three doses 
of a study vaccine and who contributed to effi-
cacy surveillance, starting 14 days after the ad-
ministration of the third dose of a study vaccine. 
The intention-to-treat population included all 
participants who received at least one dose of a 
study vaccine.
Data were censored for the first 6000 children 
in the older age category 14 months after the 
administration of the first dose of vaccine or at 
the date of emigration, withdrawal of consent, 
or death. For analysis of the pooled age catego-
ries, the time at risk ended on May 31, 2011, when 
a booster dose was given, or at the date of with-
drawal of consent or death. Estimates of vaccine 
efficacy according to study site and according to 
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the incidence of clinical or severe malaria in the 
younger age category are not yet available, owing 
to insufficient statistical power and follow-up 
time, but will be analyzed at a later time.
Adverse events were coded from clinician-
assigned diagnoses for serious adverse events 
using the preferred terms of the Medical Dictionary 
for Regulatory Activities.20 All adverse events are 
presented according to age category in the inten-
tion-to-treat population. Diagnoses for serious 
adverse events are based on all available clinical 
evidence and are not bound by stringent labora-
tory or diagnostic criteria. Therefore, they should 
not be used to infer vaccine efficacy. A formal 
analysis of vaccine efficacy against coexisting ill-
nesses is planned for the end of the study.
To preserve blinding, analyses were conduct-
ed by external statisticians using SAS software, 
version 9.2 (SAS Institute).
R esult s
Study Population
The first 6000 children 5 to 17 months of age at 
enrollment were included in the primary analysis 
of vaccine efficacy during the 12 months after the 
administration of the third dose of vaccine. Of 
these children, 4296 (71.6%) were included in the 
per-protocol analysis (Fig. 1). (The number of chil-
dren who participated according to study center 
is shown in Table 5 in the Supplementary Appen-
dix.) A survey undertaken 14 months after the 
administration of the first dose of a study vaccine 
showed that approximately 75% of children in 
the two study groups were using bed nets (Table 
6 in the Supplementary Appendix). At one center, 
enrollment was delayed, and no children from 
that center were among the first 6000 enrolled. 
At another center, study vaccines were exposed to 
temperatures outside the recommended storage 
range, leading to the exclusion of 870 children 
from the per-protocol analysis. The first 200 
participants from each center contributed to the 
analysis of reactogenicity and immunogenicity.
In total, 15,460 participants were enrolled, 
including 6537 infants 6 to 12 weeks of age and 
8923 children 5 to 17 months of age at the time 
of the first vaccination (Fig. 2). The mean follow-
up times were 9 months in the younger age cat-
egory and 18 months in the older age category 
after the administration of the first dose of a study 
vaccine (Table 7 in the Supplementary Appendix). 
Baseline demographic characteristics were similar 
in the two study groups (Table 8 in the Supple-
mentary Appendix).
Vaccine Efficacy against Clinical and Severe 
Malaria in the Older Age category
During 12 months of follow-up in the first 6000 
children in the older age category, the incidence 
of the first or only episode of clinical malaria 
meeting the primary case definition was 0.44 per 
person-year in the RTS,S/AS01 group and 0.83 
per person-year in the control group, resulting in 
a vaccine efficacy of 55.8% (97.5% confidence in-
terval [CI], 50.6 to 60.4) (Fig. 3). Evaluation of the 
proportionality of the hazard assumption showed 
that vaccine efficacy was not constant over time 
(P<0.001 by Schoenfeld residuals) (Table 9 in the 
Supplementary Appendix), with vaccine efficacy 
higher at the beginning than at the end of the 
follow-up period. Vaccine efficacy against all 
clinical malaria episodes was 55.1% (95% CI, 
50.5 to 59.3), and estimates were consistent across 
all case definitions and in both adjusted and in-
tention-to-treat analyses (Table 1).
At least one episode of severe malaria that 
met the primary case definition occurred in 57 
of 2830 children (2.0%) in the RTS,S/AS01 group 
and in 56 of 1466 children (3.8%) in the control 
group, for a vaccine efficacy of 47.3% (95% CI, 
22.4 to 64.2) (Table 2).
Vaccine Efficacy against Severe Malaria  
in the Pooled Age categories
Among children in the combined age categories, 
at least one episode of severe malaria that met 
the primary case definition occurred in 149 of 
8597 children (1.7%) in the RTS,S/AS01 group 
and in 116 of 4364 children (2.7%) in the control 
group (Table 2). The average durations of follow-
up were 16 months after the administration of 
the third dose of a study vaccine (range, 0 to 22 
months) in the older age category and 7 months 
(range, 0 to 15 months) in the younger age cate-
gory. Vaccine efficacy against severe malaria in 
the pooled age categories was 34.8% (95% CI, 
16.2 to 49.2). Vaccine efficacy was similar for the 
secondary case definition and in the intention-
to-treat population. (The clinical features of chil-
dren with severe malaria are provided in Table 10 
in the Supplementary Appendix.)
Serious Adverse Events
In the older age category, serious adverse events 
were reported in 1048 of 5949 children (17.6%; 
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95% CI, 16.7 to 18.6) in the RTS,S/AS01 group 
and in 642 of 2974 children (21.6%; 95% CI, 20.1 
to 23.1) in the control group (Table 3). In the young-
er age category, the corresponding rates were 569 
of 4358 children (13.1%; 95% CI, 12.1 to 14.1) in 
the RTS,S/AS01 group and in 293 of 2179 children 
(13.4%; 95% CI, 12.0 to 15.0) in the control group 
(Table 3).
Similar proportions of children died in each 
study group. In the older age category, 56 of 5949 
children (0.9%; 95% CI, 0.7 to 1.2) died in the 
RTS,S/AS01 group and 28 of 2974 children (0.9%; 
95% CI, 0.6 to 1.4) in the control group; in the 
younger age category, 49 of 4358 children (1.1%; 
95% CI, 0.8 to 1.5) died in the RTS,S/AS01 group 
and 18 of 2179 children (0.8%; 95% CI, 0.5 to 1.3) 
1150 Were excluded
543 Did not meet eligibility criteria
79 Withdrew consent
71 Migrated or were lost to follow-up
188 Had other reasons
269 Were enrolled in trial, but not in 
first 6000 children
259 Did not complete
vaccination and
were excluded
7 Died, had medical
withdrawal, or
were unwell
80 Withdrew consent 
or declined to
participate
121 Migrated or were
lost to follow-up
51 Had other reasons
908 Were excluded from
per-protocol analysis 
569 Had temperature
deviation in vaccine
7 Did not meet
inclusion criteria
299 Were out of interval
for dose regimen
19 Had no follow-up
data after dose 3
14 Had other reasons
442 Were excluded from
per-protocol analysis
301 Had temperature
deviation in vaccine
5 Did not meet
inclusion criteria
121 Were out of interval
for dose regimen
13 Had no follow-up
data after dose 3
2 Had other reasons
438 Did not com-
plete 14-mo
visit
32 Died
21 Withdrew
consent
382 Migrated or
were lost to
follow-up
3 Had other
reasons
193 Did not com-
plete 14-mo
visit
15 Died
15 Withdrew
consent
163 Migrated or
were lost to
follow-up
95 Did not complete
vaccination and
were excluded
3 Died, had medical
withdrawal, or
were unwell
32 Withdrew consent 
or declined to
participate
45 Migrated or were
lost to follow-up
15 Had other reasons
3997 Received dose 1
of RTS,S/AS01
(ITT population)
2003 Received dose 1
of control vaccine
(ITT population)
6000 Underwent randomization
and received study vaccine
7150 Children were assessed for eligibility
3864 Received dose 2 1952 Received dose 2
3738 Received dose 3 1908 Received dose 3
2830 Were included
in the per-protocol
population
1466 Were included
in the per-protocol
population
3300 Attended 14-mo
follow-up
(12 mo after dose 3)
1715 Attended 14-mo
follow-up
(12 mo after dose 3)
Figure 1. Enrollment of First 6000 Children in Older Age Category (5–17 Months).
AE denotes adverse event, ITT intention to treat, and SAE serious adverse event.
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in the control group. Of the 151 children who died, 
78 (52%) died in the hospital after a thorough 
medical assessment was made; 9% of deaths oc-
curred at a health facility before completion of a full 
medical assessment, and 39% occurred in the com-
munity. Causes of death were similar in the two 
groups (Table 11 in the Supplementary Appendix). 
Ten children died with a diagnosis of malaria, 
which was confirmed on blood smear in 7 children.
At least one serious adverse event that was con-
sidered to be related to a study vaccine occurred 
in 11 children in the older age category: 10 of 
5949 children in the RTS,S/AS01 group reported 
12 events (7 seizures, 3 episodes of pyrexia, 1 epi-
sode of myositis, and 1 injection-site reaction) and 
1 of 2974 children in the control group reported 
1 event (seizure). In the younger age category, seri-
ous adverse events that were considered to be re-
1798 Were excluded
1165 Did not meet eligibility criteria
2 Died
186 Withdrew consent
174 Migrated or were lost to
follow-up
271 Had other reasons
562 Did not complete vaccination and
were excluded
3 Had medical withdrawal owing to 
SAE or related AE
25 Died
8 Were withdrawn for unrelated SAE
5 Were unwell
85 Withdrew consent
249 Migrated or were lost to follow-up
14 Did not meet inclusion criteria
37 Received EPI vaccine
71 Declined to participate
38 Were out of interval for dose
regimen
27 Had other reasons
1148 Were excluded from per-protocol
analysis 
569 Had temperature deviation
       in vaccine
18 Did not meet inclusion criteria
536 Were out of interval for dose
regimen
6 Had no follow-up data after dose 3
19 Had other reasons
214 Did not complete vaccination and
were excluded
1 Had medical withdrawal owing to 
SAE or related AE
7 Died
4 Were withdrawn for unrelated SAE
3 Were unwell
41 Withdrew consent
99 Migrated or were lost to follow-up
7 Did not meet inclusion criteria
13 Received EPI vaccine
19 Declined to participate
12 Were out of interval for dose
regimen
8 Had other reasons
575 Were excluded from per-protocol
analysis 
302 Had temperature deviation
       in vaccine
14 Did not meet inclusion criteria
248 Were out of interval for dose
regimen
5 Had no follow-up data after dose 3
6 Had other reasons
10,307 Received dose 1
of RTS,S/AS01
(ITT population)
5153 Received dose 1
of control vaccine
(ITT population)
15,460 Underwent randomization
and received study vaccine
17,258 Children were assessed for eligibility
9990 Received dose 2 5039 Received dose 2
9745 Received dose 3 4939 Received dose 3
8597 Were included
in the per-protocol
population
4364 Were included
in the per-protocol
population
Figure 2. Enrollment of All Children through May 31, 2011, or Receipt of Booster Dose.
AE denotes adverse event, EPI Expanded Program on Immunization, ITT intention to treat, and SAE serious adverse event.
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lated to a study vaccine occurred in 6 children: 3 of 
4358 children in the RTS,S/AS01 group reported 
3 events (1 injection-site reaction, 1 episode of py-
rexia, and 1 episode of febrile convulsion), and 
3 of 2179 children in the control group reported 
3 events (2 episodes of pyrexia and 1 episode of 
anaphylaxis). All children who had seizures that 
were deemed to be related to a study vaccine recov-
ered from the acute event; epilepsy subsequently 
developed in 1 child.
Meningitis was reported more frequently in 
the RTS,S/AS01 group than in the control group, 
with 11 of 5949 children versus 1 of 2974 children 
in the older age category and 8 of 4358 children 
versus 1 of 2179 children in the younger age 
category, for a relative risk of 5.5 (95% CI, 0.7 to 
42.6) in the older age category and 4.0 (95% CI, 
0.5, 32.0) in the younger age category. Laboratory 
diagnosis of meningitis, indicated by culture or 
elevated white-cell count in cerebrospinal fluid, 
was made in half these cases. There was no ap-
parent temporal relationship to vaccination or 
clustering according to center.
Seizure within 7 Days after Vaccination
In the older age category, the incidence of gener-
alized convulsive seizure within 7 days after vac-
cination (according to the Brighton Collaboration 
diagnostic certainty level of 1 to 3) was 1.04 per 
1000 doses in the RTS,S/AS01 group (95% CI, 
0.62 to 1.64) and 0.57 per 1000 doses in the con-
trol group receiving rabies vaccine (95% CI, 0.19 
to 1.34), for a risk ratio of 1.8 (95% CI, 0.6 to 4.9). 
All seizures occurred in children with a history 
of fever; 23 occurred within 7 days after vaccina-
tion, and of those, 12 of 18 seizures occurred 
within 3 days after vaccination in the RTS,S/AS01 
group and 2 of 5 seizures in the control group. In 
the younger age category, the incidence of gener-
alized convulsive seizures within 7 days after vac-
cination was 0.16 per 1000 doses in the RTS,S/AS01 
group (95% CI, 0.02 to 0.57) and 0.47 per 1000 dos-
es in the control group receiving meningococcal 
vaccine (95% CI, 0.10 to 1.37), for a risk ratio of 0.3 
(95% CI, 0.1 to 2.0).
Adverse Events
Unsolicited reports of adverse events that oc-
curred within 30 days after each vaccination were 
reported with similar frequency in the two study 
groups (Table 12 in the Supplementary Appen-
dix). (The frequencies of solicited reports of 
symptoms in the intention-to-treat population 
are shown in Table 13 and Figure 3 in the Supple-
mentary Appendix.) The most frequently reported 
symptoms were pain and fever. Overall, RTS,S/
AS01 vaccine was more reactogenic than was ra-
bies vaccine, but grade 3 symptoms occurred in-
frequently.
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Control vaccine
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Figure 3. Cumulative Incidence of First or Only Episodes of Clinical Malaria 
(Primary Case Definition) in the Older Age Category.
The cumulative incidence of the primary case definition in children 5 to  
17 months of age at enrollment is shown during 12 months of follow­up 
 after the administration of the third dose of vaccine in the per­protocol 
population (Panel A) and during 14 months of follow­up after the admin­
istration of the first dose of vaccine in the intention­to­treat population 
(Panel B).
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Immunogenicity
The geometric mean titer of anti–circumsporo-
zoite antibody at enrollment was low in the two 
study groups and remained low in the control 
group (Table 14 and Fig. 4 in the Supplementary 
Appendix). One month after the administration 
of the third dose of a study vaccine, 99.9% of 
children in the RTS,S/AS01 group were positive 
Table 3. Serious Adverse Events after the First Dose of a Study Vaccine in the Intention-to-Treat Population, According to Age Category.*
Serious Adverse Event 5–17 Mo 6–12 Wk
RTS,S/AS01 Vaccine 
(N = 5949)
Rabies Vaccine 
(N = 2974)
RTS,S/AS01 Vaccine
(N = 4358)
Meningococcal Vaccine 
(N = 2179)
no. of  
children
%  
(95% CI)
no. of  
children
%  
(95% CI)
no. of  
children
%  
(95% CI)
no. of  
children
%  
(95% CI)
All children
At least one serious adverse 
event
1048 17.6 (16.7–18.6) 642 21.6 (20.1–23.1) 569 13.1 (12.1–14.1) 293 13.4 (12.0–15.0)
At least one serious adverse 
event excluding malaria
990 16.6 (15.7–17.6) 600 20.2 (18.7–21.7) 554 12.7 (11.7–13.7) 286 13.1 (11.7–14.6)
At least one fatal serious 
 adverse event†
56 0.9 (0.7–1.2) 28 0.9 (0.6–1.4) 49 1.1 (0.8–1.5) 18 0.8 (0.5–1.3)
At least one serious adverse 
event related to vaccine
10 0.2 (0.1–0.3) 1 0.0 (0.0–0.2) 3 0.1 (0.0–0.2) 3 0.1 (0.0–0.4)
At least one serious adverse 
event within 30 days after 
vaccination
310 5.2 (4.7–5.8) 181 6.1 (5.3–7.0) 191 4.4. (3.8–5.0) 96 4.4 (3.6–5.4)
Incidence in ≥0.5% of children‡
Anemia 182 3.1 (2.6–3.5) 149 5.0 (4.3–5.9) 58 1.3 (1.0–1.7) 39 1.8 (1.3–2.4)
Bronchiolitis 35 0.6 (0.4–0.8) 18 0.6 (0.4–1.0) 26 0.6 (0.4–0.9) 17 0.8 (0.5–1.2)
Bronchitis 24 0.4 (0.3–0.6) 17 0.6 (0.3–0.9) NA NA NA NA
Bronchopneumonia 54 0.9 (0.7–1.2) 37 1.2 (0.9–1.7) 28 0.6 (0.4–0.9) 16 0.7 (0.4–1.2)
Gastroenteritis 263 4.4 (3.9–5.0) 160 5.4 (4.6–6.3) 194 4.5 (3.9–5.1) 93 4.3 (3.5–5.2)
HIV infection 37 0.6 (0.4–0.9) 19 0.6 (0.4–1.0) 23 0.5 (0.3–0.8) 6 0.3 (0.1–0.6)
Malaria 383 6.4 (5.8–7.1) 297 10.0 (8.9–11.1) 116 2.7 (2.2–3.2) 74 3.4 (2.7–4.2)
Otitis media 25 0.4 (0.3–0.6) 17 0.6 (0.3–0.9) NA NA NA NA
Pneumonia 337 5.7 (5.1–6.3) 176 5.9 (5.1–6.8) 224 5.1 (4.5–5.8) 102 4.7 (3.8–5.7)
Salmonella sepsis 41 0.7 (0.5–0.9) 23 0.8 (0.5–1.2) 16 0.4 (0.2–0.6) 10 0.5 (0.2–0.8)
Sepsis 48 0.8 (0.6–1.1) 35 1.2 (0.8–1.6) 23 0.5 (0.3–0.8) 8 0.4 (0.2–0.7)
Upper respiratory tract 
 infection
55 0.9 (0.7–1.2) 37 1.2 (0.9–1.7) 21 0.5 (0.3–0.7) 11 0.5 (0.3–0.9)
Urinary tract infection 36 0.6 (0.4–0.8) 21 0.7 (0.4–1.1) NA NA NA NA
Hypoglycemia 12 0.2 (0.1–0.4) 18 0.6 (0.4–1.0) NA NA NA NA
Kwashiorkor 12 0.2 (0.1–0.4) 16 0.5 (0.3–0.9) NA NA NA NA
Malnutrition 49 0.8 (0.6–1.1) 19 0.6 (0.4–1.0) NA NA NA NA
Convulsion 55 0.9 (0.7–1.2) 37 1.2 (0.9–1.7) 24 0.6 (0.4–0.8) 15 0.7 (0.4–1.1)
Febrile convulsion 211 3.5 (3.1–4.0) 106 3.6 (2.9–4.3) 48 1.1 (0.8–1.5) 25 1.1 (0.7–1.7)
* The average follow­up was 18 months (up to 24 months) in the older age category (5 to 17 months) and 9 months (up to 17 months) in the younger 
age category (6 to 12 weeks). HIV denotes human immunodeficiency virus, and NA not applicable (because the incidence was less than 0.5%).
† More than one fatal serious adverse event could be attributed to a single child if there was more than one underlying cause of death (e.g., 
meningitis and sepsis).
‡ Events are listed according to the preferred terms in the Medical Dictionary for Regulatory Activities.
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for anti–circumsporozoite antibodies, with a geo-
metric mean titer of 621 EU per milliliter (95% 
CI, 592 to 652).
Discussion
The RTS,S/AS01 candidate malaria vaccine re-
duced clinical episodes of malaria and severe ma-
laria by approximately half during the 12 months 
after vaccination in children 5 to 17 months of 
age. These findings are robust, with narrow con-
fidence limits and similar results in the per-proto-
col and intention-to-treat populations and in the 
adjusted and unadjusted analyses. These efficacy 
results are consistent with those from phase 2 
trials.5,6
The level of protection provided by the RTS,S/
AS01 vaccine to the 6000 children 5 to 17 months 
of age was lower at the end of the 12-month 
surveillance period than shortly after vaccina-
tion. The body of data from phase 2 studies of 
RTS,S/AS01 suggests a persistence in vaccine ef-
ficacy. However, varying study designs and sta-
tistical methods have led to different interpreta-
tions of the dynamics of efficacy over time, with 
some studies suggesting persistent protection 
and others suggesting waning protection.7,21-25 
Decreasing protection over time could reflect 
waning immunity, acquisition of natural immu-
nity in the control group, or heterogeneity of ex-
posure.26 Further follow-up and evaluation of the 
effect of a booster dose will provide a better 
understanding of the relative contribution of 
these factors.
Vaccine efficacy against severe malaria in the 
pooled age categories showed a lower estimate 
than was seen in the first 6000 children in the 
older age category who were followed for 12 
months (Table 2). Although the confidence lim-
its on these estimates overlap, we have consid-
ered reasons that might explain the differing 
estimates. Immunity against severe malaria may 
have waned beyond the 12-month follow-up pe-
riod in the older age category. Alternatively, vaccine 
efficacy may have been lower in the younger age 
category for a number of possible reasons. How-
ever, the latter supposition is not supported by 
phase 2 data, which have shown similar efficacy 
against clinical malaria in younger and older 
children.6,7 The questions raised by these differ-
ent efficacy estimates should be answered by 
continuation of follow-up of children in the trial. 
In 1 year, we will report vaccine efficacy against 
clinical and severe malaria in the younger age 
category, and at study end, we will report the 
duration of efficacy in each age category.
Despite the relatively high vaccine efficacy 
against severe malaria, we did not observe a re-
duction in the rate of death from malaria or from 
any cause in the RTS,S/AS01 group. Malaria-
specific mortality was very low in the trial, rep-
resenting only 10 of the 151 reported deaths 
(6.6%). Seven of these deaths were confirmed to 
have been caused by malaria on blood smears. 
Since the rate of death from malaria was low, we 
would not expect to be able to detect a reduction 
in the rate of death from any cause unless RTS,S/
AS01 also provided protection against coexisting 
illnesses and the associated deaths. We attribute 
the very low malaria-specific mortality in this 
trial to the high level of access to high-quality 
care provided at study facilities. The low malaria-
specific mortality is unlikely to be due to mis-
classification of moderate malaria as severe ma-
laria. Children who were classified as having severe 
malaria had objective clinical markers of severe 
disease, and nearly half had two or more mark-
ers. Approximately 3% of children with clinical 
malaria and 35% of those who were hospital-
ized with malaria were classified as having se-
vere malaria, consistent with reported estimates.27 
At the end of the study, a formal analysis of vac-
cine efficacy against death will be conducted.
In the older age category, RTS,S/AS01 was 
more reactogenic than rabies vaccine in terms 
both of systemic and local effects. However, few 
reactions were severe. Generalized convulsive 
seizures in the 7 days after RTS,S/AS01 vaccina-
tion occurred at a rate of approximately 1 per 
1000 vaccine doses, a higher rate than that seen 
with the comparator rabies vaccine. All cases 
were associated with a history of fever, and all 
children recovered from the acute event. The 
increase in the rate of meningitis in the RTS,S/
AS01 group is being monitored. Additional data 
from ongoing follow-up will clarify the rela-
tionship with the study intervention. However, 
the lack of a temporal association with vaccina-
tion and low biologic plausibility suggest that 
these events are unlikely to be related to the 
vaccine.
The trial was conducted with rigorous stan-
dardization among centers and provided a high 
standard of clinical care.12 Participants from one 
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center were excluded from the per-protocol analy-
ses because vaccines at that center were exposed 
to temperatures outside the recommended range. 
However, participants at this center were included 
in the intention-to-treat analyses, with similar 
results to those in the per-protocol analyses.
Our initial results show that the RTS,S/AS01 
vaccine reduced malaria by half in children 5 to 
17 months of age during the 12 months after 
vaccination and that the vaccine has the poten-
tial to have an important effect on the burden of 
malaria in young African children. Additional 
information on vaccine efficacy among young 
infants and the duration of protection will be 
critical to determining how this vaccine could be 
used most effectively to control malaria.
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